A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

You may be eligible if

• Previously untreated active multiple myeloma starting a new treatment for the disease with one of the three established treatment regimens: VRd (bortezomib, lenalidomide, dexamethasone), DRd (daratumumab lenalidomide dexamethasone), or DVRd (daratumumab, bortezomib, lenalidomide, and dexamethasone)
• No prior treatment for myeloma
• Not receiving concurrent treatment for another active malignancy
• No more than 3 months from start of treatment